Search

Viatris Inc

Closed

SectorHealthcare

20.83 0.73

Overview

Share price change

24h

Current

Min

20.73

Max

20.86

Key metrics

By Trading Economics

Income

-207M

-325M

Sales

-7.3M

3.7B

EPS

0.71

Dividend yield

2.41

Profit margin

-8.676

Employees

30,000

EBITDA

209M

938M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+0.86% upside

Dividends

By Acuity

Dividend yield

Sector Avg

2.41%

1.98%

Next Dividend date

16 Dec 2026

Next Ex Dividend date

23 Nov 2026

Market Stats

By TradingEconomics

Market Cap

2B

23B

Previous open

20.1

Previous close

20.83

Viatris Inc Chart

Past performance is not a reliable indicator of future results.

Related News

13 Nov 2026, 20:46 UTC

Viatris Inc. is trading higher, having fluctuated earlier in the session, and is positioned above its 20-day moving average near the upper end of its one-month range.

12 Nov 2026, 23:11 UTC

Viatris Inc. is trading higher in after-market hours, reaching its highest point of the day and positioned above its 20-day moving average.

11 Nov 2026, 21:06 UTC

News

Viatris Inc. will participate in three upcoming investor conferences, including the UBS Global Biopharma Conference on November 17.

9 Nov 2026, 21:04 UTC

Viatris Inc. is moving higher, supported by rising U.S. wholesale inventories and cautious optimism from Federal Reserve officials ahead of key inflation data.

7 Nov 2026, 00:01 UTC

Viatris Inc. is trading lower in after-market hours, showing a slight decline while remaining above its 20-day moving average and near the upper end of its one-month range.

6 Nov 2026, 23:01 UTC

In after-market trading, Viatris Inc. is roughly flat compared to Friday's close, remaining above its 20-day moving average and near the upper end of its one-month range.

5 Nov 2026, 21:04 UTC

News

Viatris reports Q3 adjusted EPS of $0.71, exceeding estimates, but posts a net loss of $325.3 million and revenue of $3.75 billion, below expectations.

4 Nov 2026, 22:02 UTC

Viatris Inc. is trading higher in after-market hours, advancing alongside the broader market and remaining well above its 20-day moving average.

3 Nov 2026, 22:02 UTC

Viatris Inc. shares declined in after-market trading, remaining stable above their 20-day moving average and near the upper end of their one-month range.

2 Nov 2026, 21:09 UTC

Viatris Inc. shares fell as the broader market declined, dropping from an initial gain to the day's lowest point since Friday's close.

30 Oct 2026, 19:36 UTC

News

Viatris initiates cash tender offer to acquire Pacira BioSciences at $36.50 per share, with unanimous board support; offer expires November 16, 2026.

29 Oct 2026, 23:41 UTC

Viatris Inc. is declining in after-market trading, having retraced from a peak earlier in the session and nearing its lowest point of the day.

28 Oct 2026, 20:07 UTC

Viatris Inc. shares advanced, reaching a peak reflecting nearly 1% cumulative return earlier in the session, while overall trading activity remained routine.

27 Oct 2026, 22:41 UTC

Viatris Inc. is trading modestly lower in after-market hours, having retraced from a brief high earlier in the session.

26 Oct 2026, 20:06 UTC

News

Piper Sandler raises price target on Viatris Inc to $14.00 from $13.00 while maintaining a Neutral rating, published today at 8:02 AM ET.

23 Oct 2026, 20:13 UTC

Viatris Inc. is trading modestly higher in after-market hours, maintaining a steady position above its 20-day moving average since Friday's close.

21 Oct 2026, 19:36 UTC

News

JPMorgan raises Viatris price target to $20.00 from $18.00 while maintaining a Neutral rating, amid cautious sentiment contributing to today's decline.

20 Oct 2026, 20:51 UTC

Viatris Inc shares fell during after-market trading, continuing a downward trend since Tuesday's close despite a brief recovery earlier in the session.

19 Oct 2026, 20:13 UTC

Viatris Inc. shares advanced modestly during after-market hours, maintaining a cumulative return since the close of regular trading and positioned above its 20-day moving average.

16 Oct 2026, 23:01 UTC

News

Viatris receives FDA approval for Ryzumvi to treat presbyopia in adults and seeks U.S. partners for commercialization under a licensing agreement with Opus Genetics.

15 Oct 2026, 20:02 UTC

News

Barclays issues a bullish outlook on Viatris, citing a positive setup for Q3 and optimism for fiscal year 2027.

14 Oct 2026, 20:07 UTC

Viatris Inc shares are advancing, building on gains since Tuesday, despite pulling back from an earlier session high. The stock is trading around its one-month range midpoint.

13 Oct 2026, 19:36 UTC

Viatris Inc shares fell, continuing a downward trend that began after Monday's close, despite an initial peak in early trading.

12 Oct 2026, 20:06 UTC

Viatris Inc shares fell modestly, reflecting a broader market trend, while fluctuating around the midpoint of their one-month range.

9 Oct 2026, 23:50 UTC

In after-market trading, Viatris Inc shares advanced, reflecting upward momentum and reaching a high cumulative return since Friday's close.

8 Oct 2026, 20:13 UTC

Event

Viatris Inc announces acquisition of Pacira BioSciences for $1.65 billion, including all remaining shares not tendered in the initial offer.

7 Oct 2026, 20:08 UTC

Social Media

Viatris Inc shares are declining as the FDA review of its MR-141 drug approaches on October 17, despite earlier gains in the session.

6 Oct 2026, 20:06 UTC

Viatris Inc shares fell modestly, retracing after an initial rise and closing below Monday's close, while remaining above the 20-day moving average.

5 Oct 2026, 20:06 UTC

Viatris Inc's shares are trading roughly flat, with little change since Friday's close, remaining around the middle of its one-month trading range.

2 Oct 2026, 23:45 UTC

Viatris Inc declined in after-market hours, continuing a trend of lower prices observed over the past four sessions since Friday's close.

Peer Comparison

Price change

Viatris Inc Forecast

Price Target

By TipRanks

0.86% upside

12 Months Forecast

Average 21 USD  0.86%

High 28 USD

Low 14 USD

Based on 9 Wall Street analysts offering 12 month price targets forViatris Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

5

Buy

3

Hold

1

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
help-icon Live chat